Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joshua Wind

Neurological Surgery Washington, DC Medical Doctor

NPI 1013182294 CMS profile 227235

5215 Loughboro Rd Nw, Suite 510, Washington, DC 20016

Open in the dashboard

General payments

$73,952

95 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$90,620 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Joshua Wind of Washington, DC is reported in the CMS Open Payments database as having received $73,952 across 95 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $90,620 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,552 31
2024 General $18,609 21
2023 General $15,971 9
2022 General $17,775 11
2021 General $143 4
2020 General $8,426 9
2019 General $3,476 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joshua Wind
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Joshua Wind were reported at $9,552. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Joshua Wind Neurological Surgery median Middle half National median
2019 $3,476 $582 $138–$3,006 $163
2020 $8,426 $294 $76–$2,174 $114
2021 $143 $387 $105–$2,432 $132
2022 $17,775 $542 $139–$2,989 $149
2023 $15,971 $534 $145–$2,697 $160
2024 $18,609 $574 $155–$3,046 $164
2025 $9,552 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Zimmer Biomet Holdings, Inc. $40,913 20 payments
  2. Centinel Spine, LLC $16,938 11 payments
  3. Orthofix Medical, Inc. $9,742 9 payments
  4. Medtronic, Inc. $2,926 26 payments
  5. DePuy Synthes Products, Inc. $1,619 3 payments
  6. Stryker Corporation $980 7 payments
  7. Boston Scientific Corporation $230 2 payments
  8. Kuros Biosciences USA, Inc $170 2 payments
  9. NuVasive, Inc. $110 2 payments
  10. Medtronic USA, Inc. $88 4 payments
  11. Other $236 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $40,728 18 payments
  2. Consulting Fee $28,104 15 payments
  3. Food and Beverage $3,206 51 payments
  4. Travel and Lodging $1,915 11 payments
Products named General payments · program years 2019–2025
  1. WalterLorenz Surgical Assist Arm $30,826 10 payments
  2. PRODISC C SK $15,563 10 payments
  3. Walter $9,902 8 payments
  4. M6-C $4,061 2 payments
  5. MAZOR X SYSTEM $2,514 18 payments
  6. PRODISC C VIVO $1,375 1 payment
  7. N/A $383 3 payments
  8. MAKO $275 2 payments
  9. VITOSS $270 2 payments
  10. WaveWriter Alpha Prime 16 $230 2 payments
  11. Other $1,697 34 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

48

Median for Neurosurgery: 83

Drug cost

$477

Median for Neurosurgery: $872

Branded share of claims

0%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 23 $217
Methocarbamol Generic 14 $181
Methylprednisolone Generic 11 $80

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$108,014

Medicare's payments for the services billed

Medicare patients

317

Average age 77

Services billed

613

170 women, 147 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 32%
Diabetes 29%
Depression 27%
Chronic kidney disease 26%
Osteoporosis 24%
Atrial fibrillation 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

95 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record